It is generally accepted that recent advances in anticancer agents have contributed
significantly to the improvement of both the disease-free survival and quality of life in cancer …

Accurate DNA replication and repair is essential for proper development, growth and tumor-
free survival in all multicellular organisms. A key requirement for the maintenance of …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Management of patients with lung cancer continues to pose a considerable challenge to
today's oncologist. While treatment may be curative in the early stages of the disease, the …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …

Introduction: We evaluated the ability of histopathologic response criteria to predict overall
survival (OS) and disease-free survival (DFS) in patients with surgically resected non-small …

Background RRM1, the regulatory subunit of ribonucleotide reductase, is involved in
carcinogenesis, tumor progression, and the response of non–small-cell lung cancer to …

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The
disappointing 5-year survival rate of below 5% stems from drug resistance to all known …

Therapeutic progress in adrenocortical carcinoma (ACC) is severely hampered by its low
incidence. Platinum-based chemotherapies are the most effective cytotoxic treatment …

Despite a growing interest in development of non-cytotoxic targeted agents, systemic
chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) …